Research Triangle Park, NC, USA and Cambridge, UK, 25 May 2021 -- Inivata, a leader in liquid biopsy, today announced a collaboration with F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, for the use of Inivata’s RaDaR technology.
News
Funds will be used to advance pre-clinical and manufacturing development programmes and prepare for clinical studies.
Leeds, UK, 13 May 2021: LUNAC Therapeutics (LUNAC), a UK-based drug discovery company focused on the development of advanced life-saving anticoagulants, announces it has raised £4.75 million in an additional financing round.
In a recent article in the New Scientist clinical trials supplement Dr Jorg Taubel, Scientific Lead at Richmond Research Institute, highlights the importance of reducing the risk to patients in phase I clinical trials.
As medicines become more personalised it will become necessary to conduct phase I trials directly with the target population. This must be approached with caution and improvements to phase I to trial design must be made before transferring the well-established healthy volunteer tool kit to patients who will often have complicated medical histories.
Cambridge, UK, 20th May 2021: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation study partnership with Eli Lilly and Company (“Lilly”).
OXFORD and TORONTO, May 17th, 2021 - PrecisionLife Ltd. (“PrecisionLife”), the leading combinatorial analytics company driving understanding of disease biology and patient stratification, and Cyclica Inc. (“Cyclica”), the partner of choice for data-driven drug discovery, announce that they have entered into a strategic partnership to co-market and offer their complementary computational platforms as an integrated drug discovery factory.
Cambridge, 19th May 2021
Cambridge, UK, 18 May 2021 – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, today announced a target discovery, option and license agreement with Janssen Biotech, Inc.
The latest issue of Sequence looks at key legal and business issues affecting the sector.
Science park investment/ Patents for ground-breaking inventions/ Shaping the EU-UK relationship/ The new life sciences legal framework and much more:
https://update.mills-reeve.com/12/2613/may-2021/life-sciences---sequence...
Giggabox is set to dramatically scale its Virtual & Hybrid Events offerings to clients as we have secured sizeable investment. This funding has been received from First Enterprise – Enterprise Loans through the Midlands Engine Investment Fund (MEIF). These extra resources will be utilised for the purchase of additional remote digital production equipment and for hiring seven new production and technical employees to help meet the growing demand for live online conferences, product launches, and digital events.
001 Limited, an independent commercial energy and utility specialists, have recently joined One Nucleus and are excited to start connecting with fellow members from the Life Science industry.
Since 2001, 001 Limited has been using its expertise and experience of the energy market to help businesses across all industries to source sustainable solutions, secure competitive utility contracts and recover savings through conducting historic audits.